The KarMMa trial is a clinical study evaluating the efficacy and safety of ide-cel, a CAR T-cell therapy, in patients with multiple myeloma who have undergone multiple prior treatments. Designed to assess key endpoints such as overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), the trial reported a 2-year PFS of 63%, indicating favorable outcomes, particularly in high-risk populations. Notably, baseline immune scores were predictive, with high-risk patients achieving a PFS of 25 months compared to just 6 months in low-risk counterparts. Data from the trial were presented at the ASH24 and IMS24 conferences, with notable contributions from experts including Bruno Paiva, Rahul Banerjee, MD, FACP, and Nico Gagelmann, who provided insights into the immune profiling and clinical implications of the findings.